Home LiteratureArticle Details
PMID: 17699539 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review Systematic Review

A systematic review of the association between circulating concentrations of C reactive protein and cancer.

Journal of epidemiology and community health ·Vol. 61 ·No. 9 ·2007-09-00 ·Pages 824-33

Heikkilä K, Ebrahim S, Lawlor DA

Abstract

The objective of this study was to review and summarise the published evidence for an association between circulating concentrations of C reactive protein (CRP) and cancer through a systematic review. 90 discrete studies were identified. 81 (90%) were prevalent case-control or cross-sectional studies, and only 9 studies had a prospective design. In most prevalent studies, CRP concentrations were found to be higher in patients with cancer than in healthy controls or controls with benign conditions. Of the nine large prospective studies identified in this review, four reported no relationship between circulating CRP levels and breast, prostate or colorectal cancers, and five studies found that CRP was associated with colorectal or lung cancers. Most of the studies evaluating CRP as a diagnostic marker of cancer did not present relevant statistical analyses. Furthermore, any association reported in the prevalent studies might reflect reverse causation, survival bias or confounding. The prospective studies provided no strong evidence for a causal role of CRP in cancer. Instead of further prevalent studies, more large prospective studies and CRP gene-cancer association studies would be valuable in investigating the role of CRP in cancer.

MeSH Terms
Biomedical Research C-Reactive Protein/analysis,metabolism Female Humans Male Neoplasms/immunology United Kingdom
Chemicals
C-Reactive Protein
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Heikkilä Katriina
Department of Social Medicine, University of Bristol, Canynge Hall, Whiteladies Road, Bristol, UK. k.heikkila@bristol.ac.uk
Ebrahim Shah
Lawlor Debbie A
References (125)
125 references, click to expand
  1. Interleukin-18 in multiple myeloma patients: serum levels in relation to response to treatment and survival.
    Leuk Res. 2004 Mar;28(3):259-66 PMID: 14687621
  2. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status.
    Int J Cancer. 2002 Mar 1;98(1):84-91 PMID: 11857390
  3. C-reactive protein for detection and follow-up of bacterial and fungal infections in severely neutropenic patients with acute leukaemia.
    Eur J Cancer Clin Oncol. 1985 May;21(5):557-62 PMID: 4007021
  4. Value of acute-phase proteins in the differential diagnosis of acute scrotum.
    Eur Urol. 2001 Feb;39(2):215-21 PMID: 11223683
  5. [Diagnostic value of biochemical tumor markers in brain tumors. Review of the literature and own experience with serum analysis of sialic acid (NANA), carcinoembryonic antigen (CEA) and neuron-specific enolase (NSE)].
    Zentralbl Neurochir. 1990;51(3):129-37 PMID: 2092546
  6. Asthma, body mass index, and C-reactive protein among US adults.
    J Asthma. 2003;40(7):733-9 PMID: 14626329
  7. Serum proinflammatory cytokines and its relationship to clinical parameters in lung cancer patients with reactive thrombocytosis.
    Respir Med. 2002 Aug;96(8):553-8 PMID: 12195834
  8. Fibrinogen, C-reactive protein and coronary heart disease: does Mendelian randomization suggest the associations are non-causal?
    QJM. 2004 Mar;97(3):163-6 PMID: 14976273
  9. Clinical utility of different tumor markers in breast cancer and gynecological malignancies.
    Cancer Detect Prev. 1983;6(1-2):221-5 PMID: 6603907
  10. The enhanced inflammatory response in non-small cell lung carcinoma is not reflected in the alveolar compartment.
    Respir Med. 1998 Jan;92(1):76-83 PMID: 9519229
  11. Bias in relative odds estimation owing to imprecise measurement of correlated exposures.
    Stat Med. 1992 May;11(7):953-61 PMID: 1604073
  12. [Prognostic factors and markers of activity in multiple myeloma (results of the Cooperative Group for Diagnosis and Treatment of Multiple Myeloma)].
    Cas Lek Cesk. 2000 Apr 12;139(7):208-12 PMID: 10916207
  13. C-reactive protein (CRP) as tumor marker in pediatric and adolescent patients with Hodgkin disease.
    Med Pediatr Oncol. 2003 Jul;41(1):21-5 PMID: 12764738
  14. Peri- and postoperative changes in serum levels of four tumor markers and three acute phase reactants in benign and malignant gynecological diseases.
    Arch Gynecol Obstet. 1992;251(2):69-78 PMID: 1374604
  15. Systemic inflammation correlates with increased expression of skeletal muscle ubiquitin but not uncoupling proteins in cancer cachexia.
    Oncol Rep. 2005 Jul;14(1):257-63 PMID: 15944798
  16. Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity.
    Am J Hematol. 2003 Apr;72(4):229-33 PMID: 12666132
  17. Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia.
    Blood. 2005 Jul 1;106(1):362-7 PMID: 15774616
  18. Prospective assessment of the role of five tumour markers in breast cancer.
    Cancer Immunol Immunother. 1991;33(6):403-10 PMID: 1878893
  19. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer.
    Prostate. 2004 Jun 1;59(4):393-400 PMID: 15065087
  20. Discrimination between malignant and nonmalignant ascites using serum and ascitic fluid proteins in a multivariate analysis model.
    Dig Dis Sci. 2000 Mar;45(3):500-8 PMID: 10749324
  21. Fibrinolytic activity in multiple myeloma.
    Am J Hematol. 2003 Dec;74(4):231-7 PMID: 14635202
  22. Serum level of interleukin-16 in multiple myeloma patients and its relationship to disease activity.
    Am J Hematol. 2004 Feb;75(2):101-6 PMID: 14755377
  23. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
    Hepatogastroenterology. 1999 Jan-Feb;46(25):220-7 PMID: 10228796
  24. [Clinical significance of erythrocyte sedimentation rate, C-reactive protein and serum lactate dehydrogenase levels in the diagnosis, prognosis and treatment monitoring of children suffering from cancer].
    Med Wieku Rozwoj. 2004 Oct-Dec;8(4 Pt 2):1081-9 PMID: 15951603
  25. Endemic African Kaposi's sarcoma is not associated with immunodeficiency.
    Int J Cancer. 1985 Jul 15;36(1):49-54 PMID: 4018905
  26. Peripheral blood cells from weight-losing cancer patients control the hepatic acute phase response by a primarily interleukin-6 dependent mechanism.
    Int J Oncol. 1999 Oct;15(4):823-7 PMID: 10493968
  27. C-reactive protein and its role in metabolic syndrome: mendelian randomisation study.
    Lancet. 2005 Dec 3;366(9501):1954-9 PMID: 16325697
  28. Serum IL-6, TNFalpha and CRP levels in Greek colorectal cancer patients: prognostic implications.
    World J Gastroenterol. 2005 Mar 21;11(11):1639-43 PMID: 15786541
  29. Cytokine regulation of constitutive production of interleukin-8 and -6 by human pancreatic cancer cell lines and serum cytokine concentrations in patients with pancreatic cancer.
    Int J Oncol. 2002 Oct;21(4):881-6 PMID: 12239630
  30. Serum levels of leptin in multiple myeloma patients and its relation to angiogenic and inflammatory cytokines.
    Int J Biol Markers. 2004 Jan-Mar;19(1):52-7 PMID: 15077927
  31. Adiponectin and the systemic inflammatory response in weight-losing patients with non-small cell lung cancer.
    Cytokine. 2004 Jul 21-Aug 7;27(2-3):90-2 PMID: 15242698
  32. C-reactive protein levels and subsequent cancer outcomes: results from a prospective cohort study.
    Eur J Cancer. 2006 Apr;42(6):704-7 PMID: 16513341
  33. A prospective study of serum C-reactive protein and colorectal cancer risk in men.
    Cancer Res. 2006 Feb 15;66(4):2483-7 PMID: 16489056
  34. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumour necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer.
    Clin Sci (Lond). 1999 Jan;96(1):83-7 PMID: 9857110
  35. Increased expression of cytokines in liver and serum in patients with extrahepatic diseases.
    J Gastroenterol. 1996 Aug;31(4):538-45 PMID: 8844475
  36. Inflammation and cancer.
    Nature. 2002 Dec 19-26;420(6917):860-7 PMID: 12490959
  37. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers.
    Prev Med. 2005 Aug;41(2):651-6 PMID: 15917065
  38. Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum.
    Clin Exp Immunol. 1978 Apr;32(1):119-24 PMID: 668189
  39. Serum acute-phase proteins and immunoglobulins in patients with gliomas.
    Cancer Res. 1979 Feb;39(2 Pt 1):542-4 PMID: 83910
  40. Elevations of serum C-reactive protein occur independently of circulating interleukin-6 concentrations in patients with lung-cancer.
    Oncol Rep. 1995 Mar;2(2):215-9 PMID: 21597715
  41. Higher levels of interleukin-6 in cystic fluids from patients with malignant versus benign ovarian tumors correlate with decreased hemoglobin levels and increased platelet counts.
    Cancer. 1995 Feb 15;75(4):1004-9 PMID: 7842401
  42. C-reactive protein and the risk of incident colorectal cancer.
    JAMA. 2004 Feb 4;291(5):585-90 PMID: 14762037
  43. Circulating concentrations of "free" leptin in relation to fat mass and appetite in gastrointestinal cancer patients.
    Nutr Cancer. 2002;44(2):157-60 PMID: 12734062
  44. Association of C-reactive protein with blood pressure and hypertension: life course confounding and mendelian randomization tests of causality.
    Arterioscler Thromb Vasc Biol. 2005 May;25(5):1051-6 PMID: 15731495
  45. Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer.
    Med Oncol. 2005;22(4):353-8 PMID: 16260852
  46. C-reactive protein levels are not associated with increased risk for colorectal cancer in women.
    Ann Intern Med. 2005 Mar 15;142(6):425-32 PMID: 15767620
  47. The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.
    Br J Cancer. 2004 Dec 13;91(12):1993-5 PMID: 15570310
  48. Is C-reactive protein specific for vascular disease in women?
    Ann Intern Med. 2002 Apr 2;136(7):529-33 PMID: 11926788
  49. Immunohistochemical expression of C-reactive protein in squamous cell carcinoma of the esophagus - significance as a tumor marker.
    Cancer Lett. 2003 Mar 20;192(1):89-95 PMID: 12637157
  50. Retinol-binding protein, acute phase reactants and Helicobacter pylori infection in patients with gastric adenocarcinoma.
    World J Gastroenterol. 2005 Dec 7;11(45):7174-8 PMID: 16437667
  51. Stress response to hepatectomy in patients with a healthy or a diseased liver.
    World J Surg. 2003 Jul;27(7):761-4 PMID: 14509501
  52. Monitoring multiple angiogenesis-related molecules in the blood of cancer patients shows a correlation between VEGF-A and MMP-9 levels before treatment and divergent changes after surgical vs. conservative therapy.
    Int J Cancer. 2006 Feb 1;118(3):755-64 PMID: 16114015
  53. Value of serum C-reactive protein measurement in the detection of hepatocellular carcinoma superimposed on liver cirrhosis.
    J Cancer Res Clin Oncol. 1994;120(4):229-32 PMID: 7507117
  54. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma.
    J Clin Pathol. 2004 Aug;57(8):856-60 PMID: 15280408
  55. Interleukin-6 and acute-phase proteins in head and neck cancer.
    Eur Arch Otorhinolaryngol. 1995;252(3):159-62 PMID: 7544987
  56. The relationship between interleukin-6 and C-reactive protein in patients with benign and malignant prostate disease.
    Br J Cancer. 2004 Nov 15;91(10):1755-7 PMID: 15505624
  57. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
    Ann Hematol. 2003 Jan;82(1):19-23 PMID: 12574959
  58. Nanoprobe-based affinity mass spectrometry for selected protein profiling in human plasma.
    Anal Chem. 2005 Sep 15;77(18):5990-7 PMID: 16159132
  59. Aging, longevity, inflammation, and cancer.
    Ann N Y Acad Sci. 2004 Dec;1028:1-13 PMID: 15915584
  60. C-reactive protein is significantly associated with prostate-specific antigen and metastatic disease in prostate cancer.
    BJU Int. 2005 May;95(7):961-2 PMID: 15839913
  61. C-reactive protein and erythrocyte sedimentation rate in differential diagnosis between infections and neoplastic fever in patients with solid tumours and lymphomas.
    Support Care Cancer. 2001 Mar;9(2):124-8 PMID: 11305070
  62. Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer.
    Clin Cancer Res. 1999 Jun;5(6):1369-79 PMID: 10389921
  63. Antibody microarray profiling reveals individual and combined serum proteins associated with pancreatic cancer.
    Cancer Res. 2005 Dec 1;65(23):11193-202 PMID: 16322270
  64. A simple C-reactive protein measurement for the differentiation between tuberculous and malignant pleural effusion.
    Respirology. 2004 Mar;9(1):66-9 PMID: 14982604
  65. Serum levels of interleukin 6 in patients with lung cancer.
    Br J Cancer. 1995 May;71(5):1095-8 PMID: 7734307
  66. The acute phase response in breast carcinoma.
    Anticancer Res. 2002 Mar-Apr;22(2B):1289-93 PMID: 12168939
  67. Micronutrients in gastrointestinal cancer.
    Br J Cancer. 1993 Dec;68(6):1195-8 PMID: 8260373
  68. Immunoglobulin A, G and E levels in Egyptians with cancer: influence of schistosomiasis.
    Int J Cancer. 1984 Jun 15;33(6):771-5 PMID: 6735523
  69. [Acute phase proteins in monoclonal gammapathies].
    Pathol Biol (Paris). 1991 Oct;39(8):769-73 PMID: 1722302
  70. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition?
    Cytokine. 2002 Jul 7;19(1):21-6 PMID: 12200109
  71. Increased soluble intercellular adhesion molecule-1, breast cancer and the acute phase response.
    Blood Coagul Fibrinolysis. 2002 Mar;13(2):165-8 PMID: 11914659
  72. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
    J Exp Clin Cancer Res. 2000 Sep;19(3):301-7 PMID: 11144523
  73. [Characterization of pregnancy-associated glycoproteins as acute phase proteins. Their demonstration in serums of patients with neoplasms and other diseases].
    Arch Gynakol. 1972;213(1):54-72 PMID: 4629806
  74. The diagnosis of pleural effusions--are cancer markers clinically helpful?
    Med Pediatr Oncol. 1984;12(1):68-72 PMID: 6199656
  75. Elevated circulating interleukin-6 is associated with an acute-phase response but reduced fixed hepatic protein synthesis in patients with cancer.
    Ann Surg. 1991 Jan;213(1):26-31 PMID: 1898691
  76. Defense proteins and immune complexes in the blood serum of women with inflammatory and neoplastic lesions of the ovary.
    Am J Reprod Immunol. 1983 Jul-Aug;4(1):11-20 PMID: 6194700
  77. Inflammation and the development of pancreatic cancer.
    Surg Oncol. 2002 May;10(4):153-69 PMID: 12020670
  78. Plasma C-reactive protein and risk of cancer: a prospective study from Greece.
    Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):381-4 PMID: 16492932
  79. Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue.
    Kidney Int. 2005 Nov;68(5):2103-10 PMID: 16221209
  80. Serum interleukin-6 has no discriminatory role in paraproteinaemia nor a prognostic role in multiple myeloma.
    Br J Haematol. 1999 Oct;107(1):132-8 PMID: 10520033
  81. The relationship between reduced vitamin antioxidant concentrations and the systemic inflammatory response in patients with common solid tumours.
    Clin Nutr. 2002 Apr;21(2):161-4 PMID: 12056790
  82. Inflammation and cancer: back to Virchow?
    Lancet. 2001 Feb 17;357(9255):539-45 PMID: 11229684
  83. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients.
    Eur J Cancer. 2000 May;36(7):889-94 PMID: 10785594
  84. Serum neural cell adhesion molecule differentiates multiple myeloma from paraproteinemias due to other causes.
    Blood. 1996 Jan 15;87(2):712-6 PMID: 8555495
  85. Patients with spontaneous bacterial peritonitis, and malignant and cirrhotic ascites.
    J Natl Med Assoc. 2005 Feb;97(2):276-80 PMID: 15712792
  86. Vitamin antioxidants, lipid peroxidation and the systemic inflammatory response in patients with prostate cancer.
    Int J Cancer. 2006 Feb 15;118(4):1051-3 PMID: 16106418
  87. Correlation between serum prostate-specific antigen and alpha-1-antitrypsin in men without and with prostate cancer.
    J Lab Clin Med. 2006 Apr;147(4):174-81 PMID: 16581345
  88. Renal cell carcinoma-associated immune impairment that may interfere with the response to cytokine therapy.
    Neoplasma. 1999;46(3):141-9 PMID: 10613588
  89. Elevated serum levels of C-reactive protein are indicative of a poor prognosis in patients with esophageal cancer.
    Dis Esophagus. 2005;18(3):146-50 PMID: 16045574
  90. Obesity is an important determinant of baseline serum C-reactive protein concentration in monozygotic twins, independent of genetic influences.
    Circulation. 2004 Jun 22;109(24):3022-8 PMID: 15184288
  91. Indices of immune activation after bronchial carcinoma surgery.
    Ann Univ Mariae Curie Sklodowska Med. 2003;58(1):161-6 PMID: 15314978
  92. Use of pleural fluid C-reactive protein in laboratory diagnosis of pleural effusions.
    Eur J Med. 1992 Jul-Aug;1(4):201-7 PMID: 1341445
  93. Serum proinflammatory mediators at different periods of therapy in patients with multiple myeloma.
    Mediators Inflamm. 2005 Aug 14;2005(3):171-4 PMID: 16106104
  94. Pretreatment serum levels of C-reactive protein, alpha 1-antitrypsin, haptoglobin, alpha 1-acid glycoprotein and tissue polypeptide antigen in cervical carcinoma.
    Eur J Gynaecol Oncol. 1991;12(5):375-83 PMID: 1717278
  95. Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicular cancer.
    Eur J Cancer. 2004 Mar;40(5):701-6 PMID: 15010071
  96. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer.
    Cancer. 2005 Jan 15;103(2):377-82 PMID: 15558809
  97. Associations of fibrinogen and C-reactive protein with prevalent and incident coronary heart disease are attenuated by adjustment for confounding factors. British Women's Heart and Health Study.
    Thromb Haemost. 2005 May;93(5):955-63 PMID: 15886815
  98. Plasma C-reactive protein and risk of colorectal cancer in a nested case-control study: Japan Public Health Center-based prospective study.
    Cancer Epidemiol Biomarkers Prev. 2006 Apr;15(4):690-5 PMID: 16614110
  99. Reevaluation of C-reactive protein in cancer sera by radioimmunoassay and radial immunodiffusion. I. Diagnostic value and use in battery of conventional tumor markers.
    Oncology. 1981;38(5):286-91 PMID: 6115350
  100. Longitudinal study of resting energy expenditure, body cell mass and the inflammatory response in male patients with non-small cell lung cancer.
    Lung Cancer. 2001 Jun;32(3):307-12 PMID: 11390012
  101. What can mendelian randomisation tell us about modifiable behavioural and environmental exposures?
    BMJ. 2005 May 7;330(7499):1076-9 PMID: 15879400
  102. Serum tumor markers in non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
    Int J Biol Markers. 1993 Jan-Mar;8(1):14-20 PMID: 8496627
  103. Acute-phase reactants and plasma trace element concentrations in non-small cell lung cancer patients and controls.
    Nutr Cancer. 1997;28(3):308-12 PMID: 9343841
  104. Effect of internal biliary drainage on plasma levels of endotoxin, cytokines, and C-reactive protein in patients with obstructive jaundice.
    World J Surg. 2002 Nov;26(11):1328-32 PMID: 12297927
  105. C-reactive protein, procalcitonin, interleukin-6, vascular endothelial growth factor and oxidative metabolites in diagnosis of infection and staging in patients with gastric cancer.
    World J Gastroenterol. 2004 Apr 15;10(8):1115-20 PMID: 15069709
  106. The clinical and prognostic significance of erythrocyte sedimentation rate (ESR), serum interleukin-6 (IL-6) and acute phase protein levels in multiple myeloma.
    Clin Lab Haematol. 2003 Feb;25(1):41-6 PMID: 12542441
  107. High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer.
    Gynecol Oncol. 1998 Jun;69(3):248-52 PMID: 9648596
  108. Distinctive serum protein profiles involving abundant proteins in lung cancer patients based upon antibody microarray analysis.
    BMC Cancer. 2005;5:110 PMID: 16117833
  109. Changes in micronutrient concentrations following anti-inflammatory treatment in patients with gastrointestinal cancer.
    Nutrition. 2000 Jun;16(6):425-8 PMID: 10869897
  110. Alterations of humoral immunity in patients with gastric cancer.
    Asian Pac J Allergy Immunol. 1988 Jun;6(1):7-10 PMID: 3166645
  111. Secretion of acute-phase proteins before and after hepatocellular carcinoma resection.
    J Formos Med Assoc. 1999 Feb;98(2):85-91 PMID: 10083762
  112. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease.
    Arterioscler Thromb Vasc Biol. 2003 Nov 1;23(11):2063-9 PMID: 12842840
  113. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort.
    Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2413-8 PMID: 16214925
  114. Inflammation as a tumor promoter in cancer induction.
    Semin Cancer Biol. 2004 Dec;14(6):433-9 PMID: 15489136
  115. Colorectal cancer and serum C-reactive protein levels: a case-control study nested in the JACC Study.
    J Epidemiol. 2005 Jun;15 Suppl 2:S185-9 PMID: 16127232
  116. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis.
    Am J Clin Oncol. 2003 Apr;26(2):135-40 PMID: 12714883
  117. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.
    Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9 PMID: 11504947
  118. Role of serum C-reactive protein as a marker of hepatocellular carcinoma in patients with cirrhosis.
    J Gastroenterol Hepatol. 2000 Apr;15(4):417-21 PMID: 10824887
  119. Increased levels of serum transferrin receptor and serum transferrin receptor/log ferritin ratios in men with prostate cancer and the implications for body-iron stores.
    J Lab Clin Med. 2004 Oct;144(4):176-82 PMID: 15514585
  120. Selection of patients with monoclonal gammopathy of undetermined significance is mandatory for a reliable use of interleukin-6 and other nonspecific multiple myeloma serum markers.
    Acta Haematol. 1994;92(1):1-7 PMID: 7985475
  121. What is the role of the insulin-like growth factor system in the pathophysiology of cancer cachexia, and how is it regulated?
    Clin Endocrinol (Oxf). 2002 Jun;56(6):723-33 PMID: 12072041
  122. Effect of inflammation on measures of antioxidant status in patients with non-small cell lung cancer.
    Am J Clin Nutr. 1997 Nov;66(5):1283-5 PMID: 9356549
  123. Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress.
    J Mol Med (Berl). 2003 Oct;81(10):664-73 PMID: 12928788
  124. C reactive protein in pancreatic cancer and chronic pancreatitis.
    Ann Clin Res. 1988;20(6):414-6 PMID: 3218913
  125. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?
    Int J Epidemiol. 2003 Feb;32(1):1-22 PMID: 12689998
Article Info
Journal
Journal of epidemiology and community health
Abbr.
J Epidemiol Community Health
ISSN
0143-005X
DOI
10.1136/jech.2006.051292
Email
k.heikkila@bristol.ac.uk
Published
2007-09-00
Pages
824-33
Language
English
Region
England
NLM ID
7909766
PMCID
PMC2703800
Subset
IM
Grants
Medical Research Council · G0600705 · United Kingdom
External Links
PubMed source DOI: 10.1136/jech.2006.051292 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2